GC
NYMX

Globeflex Capital’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Globeflex Capital’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,622
Closed -$10K – 417
2017
Q3 		$10K Hold
2,622
– – ﹤0.01% 363
2017
Q2 		$12K Hold
2,622
– – ﹤0.01% 387
2017
Q1 		$10K Buy
+2,622
New +$8.63K ﹤0.01% 437

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Globeflex Capital's NYMX Position: Q4 2017 in Review

Globeflex Capital sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2017, closing a stake of 2,622 shares — an estimated $10K sold.

Globeflex Capital first reported a position in NYMX in Q1 2017 and held it in 3 quarters. The position peaked at $12K in Q2 2017. 41 funds tracked by Wall St. Rank hold NYMX as of Q4 2017.

  • Globeflex Capital reported no remaining Nymox Pharmaceutical Corp position as of Q4 2017 after selling out during the quarter.
  • Globeflex Capital sold 2,622 Nymox Pharmaceutical Corp shares in Q4 2017, an estimated $10K.
  • Globeflex Capital first reported a position in Nymox Pharmaceutical Corp in Q1 2017 and held it in 3 quarters.
  • Globeflex Capital's Nymox Pharmaceutical Corp position peaked at $12K in Q2 2017.
  • 41 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2017.

Based on Globeflex Capital's 13F filing for Q4 2017, filed 13 Feb 2018.